Table 6

Bivariate analysis of risk factors for impairment of the inflammatory response

Factor

Impairment of the inflammatory response

P


Yes (n = 57)

No (n = 106)

RR (95%CI)


Sex

0.39 (0.19–0.79)

0.004

Male

25 (46.3)

71 (67)

Female

32 (53.7)

35 (33)

Agea

60 (50–72)

61 (48–70.2)

0.5

Hepatic cirrhosis

8 (14)

3 (2.8)

5.61 (1.26–33.83)

0.01

Immunosuppression

3 (5.3)

3 (2.8)

1.91 (0.25–14.67)

0.42

COPD

3 (5.3)

12 (11.3)

0.44 (0.1–1.72)

0.2

End-stage renal disease

3 (5.3)

4 (3.8)

1.42 (0.2–8.7)

0.7

Chronic cardiac failure

2 (3.5)

1 (0.94)

3.82 (0.2–227)

0.28

Diabetes mellitus

12 (21)

26 (24.5)

0.82 (0.35–1.9)

0.61

Noncured malignancy

4 (7)

4 (3.8)

1.92 (0.34–10.7)

0.71

Alcoholism

7 (12.3)

12 (11.3)

1.21 (0.4–3.58)

0.85

Smoking habit

10 (17.5)

30 (28.3)

0.22 (0.54–1.28)

0.12

APACHE IIa

14 (10–16.5)

10 (6–14)

<0.0001

SOFA (1)a,b

3 (2–6)

2 (1–4)

0.003

Bacteraemia

18 (31.6)

14 (13.2)

3.03 (1.28–7.22)

0.005

Genotype

-308 TNF-α promoter polymorphism

0.88 (0.33–2.37)

0.77

GG

48 (84.2)

91 (85.8)

GA/AA

9 (15.8)

15 (14.2)

TNF-β (NcoI polymorphism)

1.25 (0.61–2.54)

0.5

GG/GA

24 (42.1)

39 (28.3)

AA

33 (57.9)

67 (63.2)

IL-10-1082

1.09 (0.46–2.61)

0.8

GG

8 (14)

15 (14.2)

GA/AA

49 (86)

91 (85.8)

Genotype -308 TNF GA/AA, TNF-β AA, IL-10-1082 GG

1.48 (0.71–3.09)

0.26

Yes

18 (31.5)

43 (40.6)

No

39 (68.5)

63 (59.4)

Delayed AATa

10 (6–25)

5 (2.5–8)

<0.001


Unless otherwise stated, values are expressed as n (%). aResults expressed as median (25th to 75th percentiles). bSOFA (1) means SOFA score of the first 24 hours in the hospital. AAT, appropriate antibiotic therapy; APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; RR, relative risk; SOFA, Sequential Organ Failure Assessment.

Garnacho-Montero et al. Critical Care 2006 10:R111   doi:10.1186/cc4995

Open Data